Potentiation of carbon tetrachloride-induced hepatotoxicity in alloxan- or strepto- zotocin-diabetic rats.
Studies were performed to examine the effects of alloxan- or streptozotocin-induced diabetes on carbon tetrachloride (CCl4) liver injury. Male rats were pretreated with single i.v. injections of alloxan monohydrate (40 or 80 mg/kg) or streptozotocin (65 mg/kg). A challenging dose of CCl4 (0.1 ml/kg i.p.) was given to rats 4 days after alloxan pretreatment or 5 days after streptozotocin pretreatment, and the animals were sacrificed 24 hours later. Biochemical and morphologic evidence was obtained to show that pretreatment with the diabetogenic agents markedly enhanced CCl4-induced hepatotoxity. The challenging dose of CCl4 had no effect on the serum glutamic pyruvic transaminase (SGPT) activity in control rats. However, the administration of this dose of CCl4 to rats pretreated with 40 and 80 mg/kg of alloxan as well as to rats pretreated with streptozotocin resulted in 11-, 68-, and 32-fold increases, respectively, in SGPT activity. Hepatic triglyceride concentrations in the diabetic rats were also markedly elevated above control values after CCl4 challenge. Alloxan- or streptozotocin-pretreatment alone did not enhance these biochemical parameters of liver injury. Hepatic glucose-6-phosphatase activity, which increased in the rats given a diabetogenic agent, was lowered as a result of CCl4 injection. Insulin treatment of rats given alloxan (80 mg/kg) markedly protected against CCl4-induced hepatotoxicity. The severity of the morphologic changes in diabetic rats given CCl4 correlated with the biochemical findings.
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002252:Carbon Tetrachloride Poisoning / Q000150:complications*; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000209:etiology* / Q000473:pathology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000201:enzymology; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004357:Drug Synergism; D005952:Glucose-6-Phosphatase / Q000378:metabolism; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000032:analysis / Q000201:enzymology / Q000473:pathology; D008297:Male; D051381:Rats; D013311:Streptozocin; D014280:Triglycerides / Q000032:analysis
D001786:Blood Glucose; D007328:Insulin; D014280:Triglycerides; D013311:Streptozocin; D000410:Alanine Transaminase; D005952:Glucose-6-Phosphatase